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Abstract We assessed mismatch repair by immunohisto-
chemistry (IHC) and microsatellite instability (MSI) analysis
in an early onset endometrial cancer and a sister’s colon
cancer. We demonstrated high-level MSI and normal
expression for MLH1, MSH2 and MSH6. PMS2 failed to
stain in both tumors, strongly implicating a PMS2 defect.
This family did not meet clinical criteria for Lynch syn-
drome. However, early onset endometrial cancers in the
proband and her sister, a metachronous colorectal cancer in
the sister as well as MSI in endometrial and colonic tumors
suggested a heritable mismatch repair defect. PCR-based
direct exonic sequencing and multiplex ligation-dependent
probe ampliﬁcation (MLPA) were undertaken to search for
PMS2 mutations in the germline DNA from the proband and
her sister. No mutation was identiﬁed in the PMS2 gene.
However, PMS2 exons 3, 4, 13, 14, 15 were not evaluated by
MLPA and as such, rearrangements involving those exons
cannot be excluded. Clinical testing for MLH1 and MSH2
mutationrevealedagermlinedeletionofMLH1exons14and
15. This MLH1 germline deletion leads to an immunode-
tectable stable C-terminal truncated MLH1 protein which
based on the IHC staining must abrogate PMS2 stabilization.
To the best of our knowledge, loss of PMS2 in MLH1 trun-
cating mutation carriers that express MLH1 in their tumors
has not been previously reported. This family points to a
potential limitation of IHC-directed gene testing for sus-
pected Lynch syndrome and the need to consider compre-
hensive MLH1 testing for individuals whose tumors lack
PMS2 but for whom PMS2 mutations are not identiﬁed.
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IHC Immunohistochemistry
MSI Microsatellite instability
MLPA Multiplex ligation-dependent probe ampliﬁcation
RACE Rapid PCR ampliﬁcation of the 30 cDNA end
Introduction
Lynch syndrome, also known as hereditary non-polyposis
colorectal cancer syndrome, is characterized by autoso-
mal dominant cancer susceptibility in which mutation
carriers are at high risk for colon, endometrial, gastric,
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tumors [1, 2]. Lynch syndrome is genetically heteroge-
neous. Families segregate mutations in one of four DNA
mismatch repair genes: MLH1, MSH2, MSH6 or PMS2.
Tumors arise subsequent to loss of the wild-type allele.
Loss of DNA mismatch repair in these tumors leads to a
mutator phenotype. The vast majority of cancers in Lynch
syndrome mutation carriers exhibit microsatellite instabil-
ity (MSI) and show loss of one or more mismatch repair
protein [3].
Clinical diagnostic criteria were originally designed to
identify Lynch syndrome among patients with colorectal
cancer. These clinical screening strategies have proved
unreliable among women with endometrial cancer [1, 4, 5].
Different test methodologies have been employed to screen
for Lynch syndrome using some combination of MSI
analysis, immunohistochemical staining (IHC) as well as
MLH1 promoter methylation assessment and family history
ascertainmentasmeanstobettercharacterizecasesanddirect
diagnostic testing in at risk individuals [1, 6].
Patients and methods
Since 1993 our group has prospectively enrolled patients
with newly diagnosed uterine cancer in a study of defective
DNA mismatch repair. Participants have consented to
family history and molecular analyses as part of Wash-
ington University School of Medicine’s Human Research
Protection Ofﬁce approved protocols (HRPO 93-0828).
Detailed familial history is collected from participants with
apparent familial cancer predisposition (based on early
onset disease, familial aggregation or known synchronous
or metachronous malignancies associated with Lynch
syndrome). The family history data is obtained by a genetic
counselor (S.A.B.). Three-generation pedigrees are devel-
oped and periodically updated. Medical record conﬁrma-
tion is sought for all malignancies. The process and
accuracy of cancer reporting by a subset of these probands
has been previously described [7, 8].
Our general testing strategy for molecular character-
ization of these cases includes up-front MSI typing fol-
lowed by MLH1 methylation analysis. Microsatellite
analysis is performed using the ﬁve National Cancer
Institute consensus panel markers (BAT25, BAT26,
D2S123, D5S346 and D17S250) as previously described
[9, 10]. MLH1 promoter analysis by the COBRA method is
then undertaken to characterize the methylation status of
the promoter region of MLH1 [10, 11]. Cases with high-
level MSI that do not have evidence of MLH1 promoter
methylation are further characterized by IHC for MLH1,
MSH2, MSH6 and/or PMS2 as indicated. IHC is performed
using 4–5 lm-thick sections from parafﬁn-embedded
tumor tissues. Tissues are stained as previously described
using the following antibodies: MLH1 clone G168-728
(PharMingen, San Diego, CA), MSH2 clone FE11
(Oncogene Science, Cambridge, MA) and PMS2 clone
A16-4 (BD Pharmingen, San Diego, CA) [12, 13]. Directed
mutation analysis is then undertaken. PMS2 gene analysis
is carried out via exonic sequencing and multiplex ligation-
dependent probe ampliﬁcation (MLPA) as previously
described [13–16].
Results
We identiﬁed a family (kindred 1637) in which early onset
endometrial cancer in two sisters along with metachronous
colorectal cancer in one of them suggested genetic pre-
disposition (Fig. 1). This family did not meet clinical cri-
teria (Amsterdam I/II or Bethesda) for Lynch syndrome [4,
5]. Microsatellite analysis was performed on the proband’s
(III-1) endometrial cancer and the sister’s (III-2) colon
cancer. Analyses revealed high-level MSI in both tumors.
MLH1 promoter analysis by the COBRA method was then
undertaken on the proband’s (III-1) endometrial tumor.
COBRA revealed lack of epigenetic silencing of MLH1
(e.g. unmethylated promoter).
IHC performed on both endometrial tumors (III-1 and
III-2) as well as the colon tumor (III-2) demonstrated lack
of immunodetectable PMS2 with normal expression of
MLH1 and MSH2 (Fig. 1, panel). Our IHC ﬁndings
(MLH1-positive and PMS2-negative by IHC) strongly
implicated PMS2. Therefore, the PMS2 gene was analyzed
via exonic sequencing and MLPA. No mutations in PMS2
were identiﬁed. However, because exons 3, 4, 13, 14 and
15 were not evaluated by MLPA, deletion of these exons
could not be excluded. Subsequent clinical testing for
MLH1 and MSH2 mutation identiﬁed a germline deletion
of MLH1 exons 14 and 15.
Discussion
MLH1 and PMS2 form a heterodimer (MutLa) which plays
a pivotal role in the function of the mismatch repair
complex. The carboxyl-terminal domain of MLH1 is nec-
essary for MLH1-PMS2 interaction and PMS2 stabiliza-
tion. PMS2 levels are consequently undetectable or very
low in MLH1-deﬁcient cells [12, 17, 18]. Most MLH1
defects result in the complete loss or markedly reduced
levels of immunodetectable protein and secondary loss of
PMS2. The exon 14/15 MLH1 germline deletion identiﬁed
in this family results in an epitope-stable carboxyl-terminal
truncated MLH1 protein lacking the more C-terminal
PMS2 interacting domain. Based on the loss of PMS2 in
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123three different tumors arising in two carriers of this
mutation, we conclude that this abnormal MLH1 protein
fails to stabilize PMS2. Western blot analysis of cell
lysates from the proband’s endometrial primary tumor and
the probands and sister’s peripheral blood leukocytes
revealed only the truncated protein (*58 kDa) in the pri-
mary endometrial tumor whereas the peripheral blood
leukocytes demonstrated expression of both the wild type
protein (84.6 kDa) and the truncated form (data not
shown). This truncated form of MLH1 was not present in a
microsatellite stable endometrial tumor and peripheral
blood leukocytes from healthy volunteer controls.
To further characterize the effects of the deletion of
exons 14 and 15 we performed rapid PCR ampliﬁcation of
Kindred 1637
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α-MLH1 α-MSH2 α-PMS2
Fig. 1 Kindred 1637: I-1 colon
cancer, age unknown; I-2 lung
cancer, age unknown; I-3
leiomyosarcoma, died at age 54;
II-1 transitional cell carcinoma
of the bladder (microsatellite
stable), diagnosed at age 56;
III-1 endometrioid endometrial
carcinoma, diagnosed at age 48
(MSI?; IHC: PMS2 absent,
normal MLH1 and MSH2); III-2
MSI? adenocarcinoma of the
colon (MSI?; IHC: PMS2
absent, normal MLH1 and
MSH2), diagnosed at age 45 and
endometrioid endometrial
carcinoma (MSI?; IHC: PMS2
absent, normal MLH1 and
MSH2), diagnosed at age 53.
Panel: Representative
immunostains in III-2’s
endometrial cancer demonstrate
normal expression of MLH1
and MSH2 as well as absence of
PMS2. MSI?: High-level
microsatellite instability. IHC:
Immunohistochemistry
 Q  E  E  I  N  E  Q  G H  E  G  A  S  T  A  L  - 
amino acid 
510
frameshift 
519
CAGGAAGAAATTAATGAGCAGGGACATGAGGGAGCCAGCACCGCTCTTTGACCTTGCCATGCTTGCCTTAGATAGTCCAGA
GAGTGGCTGGACAGAGGAAGATGGTCCCAAAGAAGGACTTGCTGAATACATTGTTGAGTTTCTGAAGAAGAAGGCTGAGAT
exon 13 exon 16
deletion exons 14 and 15 
GCTTGCAGACTATTTCTCTTTGGAAATTGATGAGGTGTGACAGCCATTCTTATACTTCTGTTGTATTCTTCAAATAAAATT
TCCAGCCACTGTGGCCGGCATTAAGTATGAGTTTTTAAGTTAGCCCACTTTGTTAATGACTATGAGTACTAATAGCTTAAG
intron 16
TCCAGCCACTGTGGCCGGCATTAAGTATGAGTTTTTAAGTTAGCCCACTTTGTTAATGACTATGAGTACTAATAGCTTAAG
ATAAAGAAGTTTCTAGGTAATCTTGTTTGAAGGATGATGTAAAAATATAAATTTAAACTGTGAGTGACAAAATAAACTTCC
TTAATATTTGCCTACAAAAAAAAAAAAAAAAA
poly A tail
Fig. 2 RACE analysis. Sequence demonstrates deletion of exons 14 and 15 and a transcript with read through to intron 16, a frameshift and stop
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123the 30 cDNA end (RACE). The RACE analysis conﬁrmed
deletion of exons 14 and 15 with a transcript that resulted
in a premature stop and read through to intron 16 (Fig. 2).
The loss of PMS2 expression in MSI-positive tumors is
most frequently accompanied by loss of stabilization and
immunodetection of its heterodimeric partner MLH1. Most
of these cases will occur as a result of MLH1 promoter
methylation or less frequently germline mutations in
MLH1. Conversely, cases that (like our proband’s) show
loss of PMS2 with retained MLH1 expression point
towards potential deleterious mutations in PMS2. Nakag-
awa and colleagues have previously identiﬁed a missense
mutation in MLH1 associated with a similar immunohis-
tochemical ﬁnding [13].
The kindred we report represents an interesting case
study in that to our knowledge this is the ﬁrst description of
such variant Lynch syndrome family in which secondary
loss of PMS2 is caused by an epitope-stable truncating
MLH1 mutation. Cases like this point to a potential limi-
tation of IHC-directed screening for Lynch syndrome and
the need to consider comprehensive MLH1 testing for
individuals whose tumors lack PMS2 but for whom PMS2
mutations are not identiﬁed.
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